XML 118 R102.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies - Narrative (Details)
1 Months Ended 12 Months Ended
Jun. 21, 2021
USD ($)
Apr. 12, 2021
USD ($)
Mar. 20, 2021
USD ($)
shares
May 29, 2020
USD ($)
Mar. 31, 2020
USD ($)
shares
Aug. 31, 2021
USD ($)
May 31, 2021
USD ($)
ft²
May 31, 2016
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jul. 31, 2021
USD ($)
May 01, 2020
USD ($)
Feb. 14, 2020
USD ($)
Jan. 31, 2020
USD ($)
Nov. 01, 2019
USD ($)
Feb. 28, 2015
USD ($)
payment
Commitments and Contingencies                                
Number of shares issued to contingent value rights share holders | shares         123,820                      
Contingent value rights amount         $ 2,000,000.0                      
First milestone         $ 24,000,000.0                      
Contingent consideration                 $ 9,500,000              
Contractual obligation                 $ 33,189,000              
Other Commitments                                
Commitments and Contingencies                                
Area of property leased | ft²             6,352                  
Percentage of annual increase in base rent             2.50%                  
Initial monthly base rent             $ 14,300                  
Karbinal Agreement                                
Commitments and Contingencies                                
Supply and distribution commitment, period (in Years)                 20 years              
Percentage of net sales on royalty                 23.50%              
Maximum yearly make-whole payment                 $ 2,100,000              
Minimum sales per year                     70,000          
Tris Pharma, Inc.                                
Commitments and Contingencies                                
Minimum sales per year                     70,000          
Make-whole payment per unit for sales under minimum                     $ 30          
The Pediatric Portfolio                                
Commitments and Contingencies                                
Minimum annual royalties                             $ 2,100,000  
The Pediatric Portfolio | Karbinal Agreement                                
Commitments and Contingencies                                
Maximum milestone obligations           $ 3,000,000.0                    
First milestone, minimum net revenues           $ 40,000,000.0                    
Innovus                                
Commitments and Contingencies                                
Number of shares issued to contingent value rights share holders | shares     103,190   123,820                      
Contingent value rights amount     $ 1,000,000.0   $ 2,000,000.0                      
First milestone         $ 24,000,000.0                      
Second milestone     $ 30,000,000.0                          
Milestone not met during the year                 1,000,000.0              
Number of Payments | payment                               5
Total milestone payments                               $ 500,000
Contingent consideration                 300,000 $ 200,000     $ 200,000     $ 300,000
Innovus | University of lowa Research Foundation                                
Commitments and Contingencies                                
Total milestone payments                 200,000              
Contingent consideration                 100,000              
Milestone payment payable                 50,000              
Prescription Database                                
Commitments and Contingencies                                
Payment               $ 1,600,000                
Term of payment               3 years                
Contractual obligation                 905,000              
Prescription Database | The Pediatric Portfolio                                
Commitments and Contingencies                                
Payment                           $ 600,000    
First Pediatric Portfolio Fixed Obligation                                
Commitments and Contingencies                                
Payment                           210,767    
Monthly payment                 100,000,000         86,840,000    
Balloon payment                           $ 15,000,000.0    
Payments for fixed obligations to investor       $ 15,000,000.0                        
Second Pediatric Portfolio Fixed Obligation                                
Commitments and Contingencies                                
Payments for fixed obligations to investor $ 2,800,000                              
Repayments of fixed obligation 3,000,000.0                              
Loss on early satisfaction of fixed obligation                 1,300,000              
Inventories. | Hikma Pharmaceuticals USA, Inc.                                
Commitments and Contingencies                                
Payment                       $ 1,000,000.0        
Product Milestone Payments                                
Commitments and Contingencies                                
Contractual obligation                 3,000,000              
Rumpus Earn Out Payments                                
Commitments and Contingencies                                
Contractual obligation                 $ 852,000              
Over Next Six Quarters Commencing September 30, 2021 | Second Pediatric Portfolio Fixed Obligation                                
Commitments and Contingencies                                
Repayments of fixed obligation $ 500,000                              
Contingent Value Rights | Innovus                                
Commitments and Contingencies                                
Number of shares issued to contingent value rights share holders | shares     103,190   123,820                      
Contingent value rights amount     $ 1,000,000.0   $ 2,000,000.0                      
First milestone         $ 24,000,000.0                      
Second milestone     30,000,000.0                          
Milestone not met during the year     $ 1,000,000.0                          
Gain (loss) from change in fair value of CVR                   $ 300,000            
In-process R&D | Rumpus                                
Commitments and Contingencies                                
Up-front fee   $ 1,500,000                            
Payment of aggregated fees   600,000                            
Contingent consideration   67,500,000                            
In-process R&D | Maximum | Rumpus                                
Commitments and Contingencies                                
Contingent consideration   67,500,000                            
In-process R&D | Denovo Biopharma L L C | Rumpus                                
Commitments and Contingencies                                
Contingent consideration   101,700,000                            
Annual maintenance fee payable   25,000                            
License option fee payable   600,000                            
In-process R&D | Johns Hopkins University | Rumpus                                
Commitments and Contingencies                                
Contingent consideration   1,600,000                            
Minimum annual royalties   $ 5,000                            
Percentage of revenues on royalty payments   3.00%                            
In-process R&D | Beginning 2022 | Johns Hopkins University | Rumpus                                
Commitments and Contingencies                                
Minimum annual royalties   $ 20,000